Ajanta Pharma promoter pledges 28.56 lakh shares for new loan
Aayush Agrawal, trustee of Aayush Agrawal Trust, pledged 28,55,925 shares representing 2.29% of Ajanta Pharma to CTL Trusteeship Limited for a new loan. The disclosure, compliant with SEBI (SAST) Regulations, 2011, updates the total encumbered holding for the trust to 1,14,45,087 shares.
*this image is generated using AI for illustrative purposes only.
Aayush Agrawal, a promoter of Ajanta Pharma , has pledged 28,55,925 shares to secure a new loan, according to a regulatory filing submitted on June 4, 2026. The shares, representing 2.29% of the company's total share capital, were pledged in favor of CTL Trusteeship Limited. The disclosure was made in compliance with Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
The filing details the shareholding and encumbrance status of various promoter entities. Aayush Agrawal, as trustee of the Aayush Agrawal Trust, holds a total of 1,41,12,924 shares, accounting for 11.30% of the company. Prior to this transaction, the entity held 85,89,162 encumbered shares. Following the pledge creation on June 2, 2026, the total encumbered holding for this entity stands at 1,14,45,087 shares.
Other promoter entities listed in the disclosure include Gabs Investments Pvt Ltd, which recently pledged 27,70,000 shares, and trusts associated with key individuals such as Yogesh M Agrawal, Rajesh M Agrawal, and Ravi P Agrawal. While some entities hold existing encumbered shares, the recent pledge activity is specific to Aayush Agrawal as trustee of the Aayush Agrawal Trust.
The following table summarizes the shareholding and encumbrance details disclosed by the promoters:
| Name of the promoter(s) or PACs | Promoter holding (Number) | Promoter holding (%) | Promoter holding already encumbered (Number) | Promoter holding already encumbered (%) | Post event holding of encumbered shares (Number) | Post event holding of encumbered shares (%) |
|---|---|---|---|---|---|---|
| Gabs Investments Pvt Ltd | 1,25,88,393 | 10.08 | 27,70,000 | 2.22 | 27,70,000 | 2.22 |
| Yogesh M Agrawal, trustee Yogesh Agrawal Trust | 1,80,78,147 | 14.47 | - | - | - | - |
| Mannalal B Agrawal | 0 | 0.00 | - | - | - | - |
| Rajesh M Agrawal, trustee Rajesh Agrawal Trust | 1,80,78,148 | 14.47 | - | - | 60,23,920 | 4.82 |
| Ravi P Agrawal, trustee Ravi Agrawal Trust | 1,62,42,904 | 13.00 | 60,23,920 | 4.82 | 60,23,920 | 4.82 |
| Ravi P. Agrawal | 2,85,000 | 0.23 | - | - | - | - |
| Aayush M Agrawal, trustee Aayush Agrawal Trust | 1,41,12,924 | 11.30 | 85,89,162 | 6.87 | 1,14,45,087 | 9.16 |
| Aayush M. Agrawal | 30,000 | 0.02 | - | - | - | - |
| Ganga Exports represented by its partners Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal | 33,48,261 | 2.68 | - | - | - | - |
The document was signed by Aayush Agrawal, Trustee of the Aayush Agrawal Trust, and addressed to BSE Limited and the National Stock Exchange of India. The company secretary of Ajanta Pharma was also marked as a copyee.
Historical Stock Returns for Ajanta Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.23% | +7.31% | +3.57% | +18.42% | +22.01% | +141.55% |
What specific purpose will the funds raised from this new loan serve, and will it directly benefit Ajanta Pharma's operations?
How might the increased encumbrance of promoter shares impact investor confidence and the stock's liquidity in the near term?
Is there a risk of margin calls triggering further share sales if Ajanta Pharma's stock price declines significantly?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
